EX-99.1

The Myriad Transformation:

Pioneering Personalized Medicine on

a Global Scale

09/14/2015

Exhibit 99.1

Forward Looking Statements

Some of the information presented here today may contain projections

or other forward-looking statements regarding future events or the

future financial performance of the Company. These statements are

based on management’s current expectations and the actual events or

results may differ materially and adversely from these expectations.

We refer you to the documents the Company files from time to time with

the Securities and Exchange Commission, specifically, the Company’s

annual reports on Form 10-K, its quarterly reports on Form 10-Q, and

its current reports on Form 8-K. These documents identify important

risk factors that could cause the actual results to differ materially from

those contained in the Company’s projections or forward-looking

statements.

Today’s Agenda

•

The Myriad Transformation: Pioneering Personalized Medicine on a Global Scale –

Mark Capone, CEO

•

Hereditary

Cancer

Leadership

Now

and

the

Future

–

Alec

Ford,

President

Myriad

Genetic Laboratories

•

Pioneering

Companion

Diagnostics

for

DNA

Damaging

Agents

–

Lloyd

Sanders,

General Manager Oncology

•

Autoimmune

Market

Represents

Frontier

Personalized

Medicine

–

Bernie

Tobin,

President of Crescendo Biosciences

•

Making

Prolaris

Standard

Care

Urology

–

Nicole

Lambert,

General

Manager

Urology

•

Break

•

Transforming

Melanoma

Diagnosis

Through

Pioneering

Science

–

Vicki

Fish,

General

Manager Dermatology

•

Industry

Leading

Pipeline

Ensure

Growth

Opportunities

–

Jerry

Lanchbury,

CSO

•

Expanding

our

Horizons

International

Markets

–

Gary

King,

Executive

Vice

President

of International Operations

•

Five

Year

Outlook:

Increased

Growth

and

Financial

Leverage

–

Bryan

Riggsbee,

CFO

•

Q&A

U.S. Healthcare System Remains Highly

Inefficient

95%

50%

5% of patients represent 50% of healthcare costs*

*Agency for Healthcare Research and Quality

U.S. Population

Healthcare Costs

Drivers of Cost:

•

Focus on treatment

not prevention

•

Late or incorrect

diagnosis

•

Undifferentiated

treatments

•

Trial and error

approach to

pharmaceuticals

Unmatched Competitive Advantages in

Personalized Medicine

•

Profitable R&D driven molecular

diagnostic company

•

Expertise in DNA, RNA and proteins

•

Strong research capabilities: extensive

collaborations (>50 institutions and >20

pharma/bio companies)

•

Broad regulatory experience

(CLIA, FDA, CE mark)

•

Deep physician relationships (>90,000

ordering physicians since inception)

•

Extensive managed care contracts (>600)

•

Reputation for best-in-class quality for high-

complexity tests (>2 million performed)

Our Strategic Imperatives to Achieve

Our FIVE-Year

Goals

Transition & Expand the

Hereditary Cancer Market

Increase International

Contribution

Diversify the Portfolio

Significant Accomplishments Since

Last Investor Day

STRATEGIC IMPERATIVE

ACCOMPLISHMENTS

Transition and

Expand Hereditary

Cancer Market

•

6% hereditary cancer

revenue CAGR since

advent of competition

•

80%

incoming

samples

ordered

myRisk™

Hereditary

Cancer

•

Long-term pricing arrangements 45% of revenue

•

Expanded

guidelines

for

colon

endometrial

cancer

(+75,000 patients per year)

•

Breast and pancreatic expansion studies underway and will be completed in

FY16 (+90,000 patients per year)

Diversify

the Portfolio

•

Launched

new

products

internal

and

acquired)

•

Published

and

presented

250

studies

•

First

FDA

approved

laboratory

developed

test

(BRACAnalysis

CDx™)

•

Obtained

Medicare

reimbursement

for

Prolaris

•

Completed 37 companion diagnostic deals

Increase International

Contribution

•

Launched

first

kit-based

product

(EndoPredict

)

•

Direct

presence

countries

and

distribution

countries

Grew international revenue by over 300%; exiting FY15 at 4% of revenue

Our Strategic Imperatives to Achieve

Our FIVE-Year

Goals

Transition & Expand the

Hereditary Cancer Market

Increase International

Contribution

Diversify the Portfolio

Our Strategic Imperatives to Achieve

Our FIVE-Year

Goals

Transition & Expand the

Hereditary Cancer Market

Increase International

Contribution

Diversify the Portfolio

Hereditary Cancer Market Has Been More

Durable Than Investors Anticipated

Revenue has grown at

a 6% CAGR since FY13

•

Medicare price reduction

•

Higher Medicaid mix

•

Small private

payer reductions

Share loss concentrated in the

academic/genetic segment

Future Landscape for Hereditary Cancer Market

Rapid transition to panels

Panels are standard of care with

minimal gene additions

Used primarily for breast

cancer patients

Broader guidelines and

additional cancers

CLIA regulated market

FDA regulated market

Public databases fraught with

errors; Myriad has substantial

variant classification advantage

Oncology Preventive care

Preventive care >> Oncology

Oncology CDx

first then reflex

Marginal improvement in public

databases; Myriad dramatically

expands informatics advantages

CURRENT STATE:

FY20 STATE:

Sensitivity Analysis Predicts Continued Growth

Revenue in millions

Monte Carlo Simulation

Factor

Assumptions

Market

Growth

•

7%-15%

growth rate

Price

•

Price decline 0%-40%

•

Long-term contracts until

FY18 followed by…

•

FDA regulation

Market

•

Incremental share loss

of 10% to 40%

•

increase with

price decline

Our Strategic Imperatives to Achieve

Our FIVE-Year

Goals

Transition & Expand the

Hereditary Cancer Market

Increase International

Contribution

Diversify the Portfolio

Pipeline

Represents

Two-Thirds

of Opportunities

Under Development

Risk?

Diagnosis?

Prognosis?

Therapy?

Oncology

Preventive

Care

Urology

Dermatology

Neuroscience

Autoimmune

Currently

Marketed

Industry Leading Pipeline Facilitates

Long-Term Growth

$10B

$8B

$10B+

Stage

REIMBURSEMENT

Stage

VALIDATION

Stage

DISCOVERY

•

myRisk

Hereditary Cancer

•

Prolaris

•

Vectra

•

EndoPredict

•

BRACAnalysis

CDx™

•

Tumor BRACAnalysis

CDx

•

myPath

Melanoma

•

myPlan

Lung Cancer

•

myChoice

™

HRD (Platinum)

•

myChoice

HRD

™

(PARP)

•

myPlan

Renal Cancer

•

myPath

Bipolar

•

myPath

Pancreatic

Cancer

•

myPath

Psoriatic

Arthritis

•

myPath

Prostate

Cancer

•

myPath

Endometriosis

Total Addressable Market (TAM)

Ovarian Cancer, Breast Cancer, Pancreatic Cancer

Triple Negative Breast Cancer, HER2-

Breast Cancer

Ovarian Cancer, Breast Cancer, Pancreatic Cancer, Metastatic Prostate Cancer

Realistic Market Penetration Will Meet

FY20 Goals

Global TAM

$6.0B

$1.5B

$3.0B

$6.0B

$0.8B

$0.4B

12%

13%

10%

13%

Market Penetration in FY20

*Assumes only markets outside the United States

Our Strategic Imperatives to Achieve

Our FIVE-Year

Goals

Transition & Expand the

Hereditary Cancer Market

Increase International

Contribution

Diversify the Portfolio

Refined Strategy to Reflect Unique International

Market

COUNTRIES

Near-Term

Growth:

EU6 + Canada

Long-Term

Growth:

Japan, China,

and Brazil

REFERENCE TESTS

DNA

(multiple

platforms):

Companion

Diagnostics

KITS

RNA

(platform

partner):

•

EndoPredict

•

Prolaris

•

myPlan

Lung

•

myPath

Melanoma

•

myPlan

Renal

Protein

(platform

partner):

•

Vectra DA

•

myPath

Bipolar

•

myPath

Pancreatic

Worldwide Leader in Personalized Medicine

•

We are entering the golden age for

personalized medicine

•

We are pioneers of “research-driven”

and “education-centric” business

modeling for diagnostics

•

No company is better positioned to lead

this revolution in healthcare than Myriad

•

Our finest hour will be discovered in the

days ahead

Maintain Strong Market Leadership Position

Small impact from competition two years post SCOTUS decision

Continued market leadership

Clinical Accuracy:

•

Analytical

accuracy

•

Interpretation

accuracy

•

Regulatory

capability

Continued market leadership

FUTURE DIFFERENTIATION

Product Leadership:

•

Most clinically

actionable panel

•

User

friendly

report

Commercial Breadth:

•

Community physician

education

and

support

Future Landscape for Hereditary Cancer Market

Rapid transition to panels

Panels are standard of care with

minimal gene additions

Used primarily for breast

cancer patients

Broader guidelines and

additional cancers

CLIA regulated market

FDA regulated market

Public databases fraught with

errors; Myriad has substantial

variant classification advantage

Oncology Preventive care

Preventive care >> Oncology

Oncology CDx

first then reflex

Marginal improvement in public

databases; Myriad dramatically

expands informatics advantages

CURRENT STATE:

FY20 STATE:

Excellent Progress on myRisk

Conversion

and Market Expansion

Indication

Added Market

Potential

Guidelines

Colon

@5% risk

+$100M

40%

All Endometrial

+$150M

40%

Breast <60 yrs

+$150M

FY16

FY17

All Pancreatic

+$120M

FY17

MyRisk

Conversion

Sep.

2013

Sep.

2014

Sep.

2015

Sep.

2016

50%

80%

Complete

Market Expansion >$500M

Contracting

100% Analytical Accuracy Requires

Tremendous Investment

POST AMPLIFICATION PROCESS

DNA EXTRACTION AND BATCH BUILD PROCESS

TARGETED GENE SELECTION

•

85,000 base pairs that need to be

100% correct

•

0% of samples meet quality

threshold after first run on NGS

platform

•

23 major pieces of equipment from

10 vendors

•

856 distinct steps required in

testing process

•

100 proprietary software

applications

Interpretation Accuracy Impossible

With Public Databases

24,650 sequentially tested

patients at MYGN

2,017

unique

variants

34% of variants were not present in any

of the five major public databases

3%-14%

conflicting classification rate

within individual public databases

3% concordance with deleterious variants

in all five databases

VAIL STUDY

Expanding Source of Competitive Advantage

Size of database

more than

doubles again

Number of

unique variants

has almost

doubled in last

two years

Informatics Advantage Expands Over the Next Five Years

4.5x

Economics of Inaccuracy: Potential Cost >$100K

Case Study:

MYRIAD RESULT:

Favors polymorphism based upon

Pheno

(MYGN method validated

to be >99.5% accurate)

Unnecessary Procedures

Breast MRIs: $33,950

Mastectomy: $61,573

Bilateral salpingo-oophorectomy: $6,300

VARIANT BRCA2 C.9006A>T

LAB 1

LAB 2

SCENARIO ONE

Negative

RESULTS:

SCENARIO TWO

POSITIVE

RESULTS:

COMPETITIVE LAB:

Likely pathogenic based upon

no evidence (ClinVar

entry)

Analytical & Interpretation Standards Increase

With Additional Regulation

MYGN Requirements for

BRACAnalysis

CDx

FDA Approval

Analytical

Validation

>4,500 pages submitted to FDA

Clinical Validation

9 major studies

consisting of >6,000 patients

Quality

Systems

1,000 standard operating

procedures

Informatics

100 software

applications with 50,000 work

hours of validation for FDA

FDA Experience

First

ever laboratory developed test FDA

approved; planning multiple IDE submissions

Product Leadership Through the Most

Clinically Actionable Panel

19 of 25

genes in NCCN

guidelines

Prevalence

•

Prevalence of

actionable

mutations in the

tested population

of 1 in 200

patients per

gene

Clinically Actionable

•

Four or more peer reviewed publications

•

Published data on medical management

changes

Penetrance

•

to 3-fold risk vs. general population

•

Absolute cancer risk >5%

>50% of Patients Missed With Single

Syndrome Testing

41% -

Other breast

cancer genes

10% -

Genes historically not

associated with breast cancer

49% -

BRCA1 and BRCA2

50% of

Patients

Missed

Data based upon 28,000 patients

Clear, Accurate and Trusted Reports

Actionable to

Physician and Patient

•

Clear plan for each

patient based upon

personal and family

history and genetic

testing results

•

Proprietary informatics

power report; 420,000

work hours required

to develop

100% of Future Growth Derived From

Community Physicians

•

Market increasingly moving to

community setting

•

Community physicians need:

—

Substantial education and sales support

—

Extensive customer service and billing

—

Clinical support team

—

Only clinically actionable material

—

Easy to interpret report

Expenses Necessary for Community Market

Total Cost >$2,500 per test

True cost of providing a

high-quality test in the

community segment for the

most efficient provider

Additional cost for a less

efficient, lower volume lab

Maintain Strong Market Leadership Position

Small impact from competition two years post SCOTUS decision

Clinical Accuracy:

•

Analytical

accuracy

•

Interpretation

accuracy

•

Regulatory

capability

Continued market leadership

Product Leadership:

•

Most

clinically

actionable

panel

•

User-friendly

report

Commercial Breadth:

•

Community

physician

education

and

support

Pioneering Companion Diagnostics for DNA

Damaging Agents

$6B

Global

Market

Opportunity

•

FY16-FY20

Positioned to be the market leader in

CDx

for DNA damaging agents

Key Advantages in

CDx

Market

•

Reimbursement

•

Adoption

Curve

•

Barriers

Entry

•

Co-Promotion

Proven Capability

•

BRACAnalysis

CDx

Ovarian Cancer

Pioneering

Discoveries

•

myChoice

HRD

$6B Global Market Developing Over Next 5

Years

Global Market = 1.4M patients or $6.0b*

Neoadjuvant

(143,000)

Neoadjuvant

(143,000)

Pancreatic

(102,000)

Pancreatic

(102,000)

Ovarian

(58,000)

Ovarian

(58,000)

Platinum in

TNBC

(95,000)

Platinum in

TNBC

(95,000)

Platinum in

Her2-BC

(120,000)

Platinum in

Her2-BC

(120,000)

Metastatic

(107,000)

Metastatic

(107,000)

Metastatic

Prostate

(80,000)

Metastatic

Prostate

(80,000)

Adjuvant BC

(194,000)

Adjuvant BC

(194,000)

Colon

(278,000)

Gastric

(114,000)

Head &

Neck

(50,000)

Colon

(278,000)

Gastric

(114,000)

Head &

Neck

(50,000)

FY15

FY16

FY17

FY18

FY19

FY20

*Includes U.S., Canada and EU6

Uniquely Positioned To Provide

Comprehensive Testing

37%

Breast Cancer Example

Indicated

for

both

and

CDx Indication

Indicated

for

Companion

Diagnostic

Companion Diagnostic Market Dynamics Offer

Advantages

Barrier to Market Entry

•

FDA approval demonstrates high

quality; supports FDA test utilization

Speed to Market

•

Reimbursement is very quick following

FDA approval

•

Increased promotional activity –

pharma

partner

•

Adoption curve is “pharmaceutical-like”

vs. traditional diagnostic

Unique Core Competencies Provide

Sustainable Advantage

MYGN Unique

Capabilities

Intellectual

Property

Proven Regulatory

Capabilities

Global

Distribution

Complete Portfolio

of Products

Key Partnerships

in Pharma

Biotech

Proprietary

Informatics

& Database

% Positive

(Ovarian)

15%

22%

48%

Sample

Blood

Tumor

Biomarkers

BRCA1&2

Tumor BRCA1&2

Genome-wide

assessment

of DNA scar associated

Intellectual

Property

Database, process,

bioinformatics

Database, process,

bioinformatics

Currently

Marketed

FDA approved

Yes, marketed in

Europe only

platinum drugs planned in

Fall CY16

Only Company With a Complete Suite of Products

MYGN

has

three

proprietary

technologies

(LOH,

TAI,

LST)

Extensive Collaborations With >22 Clinical

Studies

Partner

Indications

Tests

AstraZeneca

(Lynparza™)

Ovarian, Metastatic BC,

Neoadjuvant

BC, Adjuvant BC,

Pancreatic, Prostate,

Gastric

Medivation

(talazoparib)

Metastatic BC,

Pancreatic

TESARO

(niraparib)

Ovarian, Metastatic

AbbVie

(veliparib)

Metastatic BC, Ovarian

Platinum

Drugs

Ovarian, TNBC, HER2-

More than 22 clinical studies underway at key

academic centers

Highly Successful Launch of

BRACAnalysis

CDx

in Ovarian Cancer

•

FDA approval Dec. 19, 2014

for BRACAnalysis

CDx

as a

companion diagnostic

•

AZN and MYGN sales forces

co-promoting the test

> 40% growth in

ovarian cancer

volume since the

launch of

BRACAnalysis

CDx

Pioneering Discovery For Assessing Genomic

Instability

DNA Repair Pathway

54,000 snapshots

tumor DNA

Three proprietary

technologies

(LOH, TAI, LST)

Produces a quantifiable score:

Each component is derived from an

algorithmic calculation. The final

score is the sum of the LOH+TAI+LST

scores: (0-100)

2015

Myriad

Genetics,

Inc.,

all

rights

reserved.

www.Myriad.com.

Only the Combination of all Three

Technologies Gives you a Complete Picture

Odds ratio of predicting pCR

for

myChoice HRD is 5.5

All 3 Technologies Required

LST

odds ratio = 4.7

TAI

odds ratio = 2.8

LOH

odds ratio = 3.3

myChoice

HRD TNBC Platinum Indication

Represents $400 Million Global TAM

Treatment with

Platinum Agents

Treatment with

Standard Chemo

TNBC: 95,000

patients globally

HRD

NEGATIVE

HRD

POSITIVE

Five Studies Demonstrate myChoice

HRD

Clinical Utility in TNBC

Based upon pooled analysis from five statistically

significant studies comprising a total of 267 patients

Over 5-fold increase in

patients with

pathological complete

response

Major Milestones Occurring in FY16

•

Laboratory:

–

Completion of FDA laboratories for Tumor

BRACAnalysis

CDx

and myChoice

HRD

•

Regulatory:

–

IDE submissions for Tumor BRACAnalysis

CDx

and myChoice

HRD

–

PMA submission for myChoice

HRD

•

Clinical:

–

TESARO NOVA study results: myChoice

HRD and niraparib

–

Final validation study completed for

myChoice

HRD for platinum in TNBC

–

Additional trials in new cancer indications

with PARP inhibitors

Early access launch

for myChoice

HRD in

Fall of 2015

Sensitivity Analysis Predicts Strong

Growth

Revenue in millions

Monte Carlo Simulation

Factor

Assumptions

Growth

•

U.S. TAM between

$500M and $1.5B

•

International mix

between 5% and 20%

•

Market penetration

between 15% and 25%

Pioneering Companion Diagnostics for DNA

Damaging Agents

$6B Global Market

Opportunity

•

FY16-FY20

Positioned to be the market leader in

CDx

for DNA damaging agents

Key Advantages in

CDx

Market

•

Reimbursement

•

Adoption Curve

•

Barriers to Entry

•

Co-Promotion

Proven Capability

•

BRACAnalysis

CDx

Ovarian Cancer

Pioneering Discoveries

•

myChoice

HRD

Autoimmune Market Is An Incredible

Opportunity

Market Opportunity

•

Autoimmune market

represents blue ocean

•

Medicare

reimbursement

•

Solid plan for

expanding private

coverage

Positioned for market success

in autoimmune

Key Advantages

•

Vectra DA validation

•

Highly predictive

Commercial Breadth

and Depth

•

Re-accelerating

growth

•

Physician adoption

•

Improved logistics

•

Practice integration

Substantial Opportunity in Blue Ocean

Autoimmune Market

•

Vectra DA for rheumatoid

arthritis is initial foray into

autoimmune market

•

Additional segments of this

market are equally compelling

•

Initiated discovery work on

psoriatic arthritis

Juvenile

Arthritis

600,000*

Psoriatic

Arthritis

2,500,000*

Ankylosing

Spondylitis

2,200,000*

Rheumatoid Arthritis

(current market)

3,000,000 patients*

Companion Dx

15 current collaborations with

major pharmaceutical companies

*Prevalence numbers for U.S., Canada and EU6 markets only (Source: Datamonitor);

Relative Risk

Low

(<30)

p = 0.008

Vectra DA Score at Baseline

SWEFOT: Vectra DA Score Highly Predictive

of Radiographic Progression

•

235 patient

SWEFOT study

•

Gold standard endpoint

of radiographic

progression at one year

•

Vectra score highly

correlated to patient

outcomes

High

(>44)

Moderate

(30-44)

Hambardzumyan, K, et al, Annals of the Rheumatic Diseases 2014. doi:10.1136/annrheumdis-2013-204986

*% Patients with

SHS >5 BL to year 1

Strategy to Reaccelerate Growth

INITIATIVE

PROGRESS TO DATE

Clarity and focus on selling message

Initiated in Q3 FY15

Increased focus on direct-to-patient

marketing

Initiated in Q1 FY16

Studies to provide additional data on

clinical interpretation

Completion in FY16

Driving depth and breadth in

Medicare market

Initiated in Q4 FY15

Driving Depth and Breadth in Medicare Market

Breadth of Use

Among Doctors

Depth in the Patient Population

Per Using Physician

~40% of rheumatologists

use the test

11 patients tested per

using physician per month

(~9% of patients seen)

Driving Breadth: Easier Logistics via National

Lab Contract

•

We have contracted with LabCorp

to use

their national network of 1,700 Patient

Service Centers (PSCs) to collect patient

blood samples beginning Aug. 31, 2015

–

24% of the rheumatology market does

not have in-office blood collection

facilities

–

28% of rheumatologists cite blood draw

logistical issues as a major barrier to

ordering more Vectra DA tests

–

37% of rheumatologists said they would

order more Vectra DA tests, if their

patients could go to a LabCorp

PSC

1,700

Patient Service Centers

Driving Depth: Practice Integration Pilot

•

Multi-specialty clinic in North

Carolina with 342 rheumatoid

arthritis patients

•

Physician goal: minimize staff

time on the phone,

communicating lab results

•

86% patient opt-in rate for PI,

and 100% patient satisfaction

rate

•

Quarterly increase of 37% in

volume; 33% of incremental

assays came from new patients

Case Study:

Practice Integration

a trial program at certain

doctor’s offices to have test

results prior

to patient visit

TEST RESULTS

PATIENT VISIT

Critical to expanding utilization in

certain practices

PHYSICIAN

REVIEW

Vectra DA Has Returned to Growth In the Last

Two Quarters

12%

sequential

volume growth

Prior to initiation of

current strategy

Post initiation of

current strategy

Tests in Thousands

33%

CAGR

Executing Plan to Expand Private Payer

Coverage in the Future

Data Mining

FY16

Retrospective Study

FY17

Prospective Study

FY18

% of

private

payer

covered

lives

Private Payer Feedback Suggests More Clinical Utility Data Required

Distribution of private payers’ data requests

Expanded Coverage Will Drive

Significant Leverage

Current Medicare reimbursement level ~$570

Gross profit

per test

Gross profit

per test

COGS per test

Expanded

private payer

coverage

Increased

efficiencies

Sensitivity Analysis Predicts Strong

Growth

Revenue in millions

Monte Carlo Simulation

Factor

Assumptions

Growth

•

15%-30%

growth rate

•

4%-10% market

penetration

Coverage

•

80%-100% payer

coverage

Autoimmune Market Represents the

Next Frontier in Personalized Medicine

•

Autoimmune market is an

incredible opportunity

•

Vectra DA is an outstanding

product, supported by robust

science

•

Current Vectra DA reimbursement

under Medicare supports over

$600M in sales

•

Penetration of Medicare market

and expansion of private payer

coverage will be two key drivers of

growth

Significant Unmet Need In Prostate Cancer

Treatment

Market Opportunity

•

Substantial unmet

clinical need

•

Expanded Medicare

coverage based on

additional clinical data

Key Advantages

•

Pioneering science

differentiation based

on gold standard

endpoints

•

Definitive active

surveillance threshold

•

Unmatched clinical

utility data

Commercial Breadth

and Depth

•

Largest urology sales

force in diagnostics

•

Increased physician

adoption

•

Increased test

utilization

Positioned to become standard of care in

the prostate cancer prognostic market

Most Prostate Cancer Patients

Inappropriately Treated

AUA

Low-Risk

Patients

Overtreatment

Problem

AUA

High-Risk

Patients

Undertreatment

Problem

TREATMENT PARADIGM

RESULTS WITHOUT

IMPROVED TOOLS

Most low-risk patients

have a low risk of prostate-

specific mortality

Yet the vast majority

are treated upfront

More than half will

experience biochemical

recurrence with single-

modality treatment alone

Yet the majority do not

receive multi-modality

treatment

AUA

Intermediate Risk

Patients

Prolaris

Is the Only Test Validated Against

Meaningful Clinical Endpoints

PUBLICATION

SAMPLE

TYPE

PATIENTS

OUTCOME

Cuzick

2011

353

HR = 1.89 per unit Prolaris

score,

p=5.6x10

-9

Cuzick

2011 (cohort 2)

TURP

337

HR = 2.92, p=6.1x10

-22

Cuzick

2012

Biopsy

349

HR = 2.02, p=8.6x10

-10

Cooperberg

2013

413

HR = 2.10, p=2.2x10

-6

Freeland 2013

Biopsy

141

HR = 2.55, p=0.0017

Bishoff

2014

Biopsy

582

HR = 1.6, p=2.4x10

-7

Bishoff

2014

Biopsy

582

HR = 5.35, p=2.1x10

-8

Cuzick

2015

Biopsy

757

HR = 2.32, p<10

-17

PROCEDE

500

Biopsy

305

Changed treatment

plans 65% of

the time 40%

25%

PROCEDE

1,000

Biopsy

1,206

Changed treatment

plans 48% of

the time 35%

13%

Prolaris

Has Substantially Stronger Prognostic

Power Than Traditional Pathology

(p<1.5x10-4)

(p<2.1x10-7)

(p<3.7x10-15)

Gleason

PSA

Prediction of Prostate Cancer Death

of the prognostic power in the

Prolaris CCR score is derived by

the independent

predictive power

of the Prolaris

test

Prolaris

>60%

Predicting Gleason

score is not enough

Redesigned Report Provides Clear and

Actionable Results

Modification

of pathology

assessment

Definitive cut-off

for which patients

are eligible for

active surveillance

Unmatched Impact on Physician

Treatment Decisions

AUA Low

Active

Surveillance

Treatment

40%

60%

69%

31%

92%

AUA

Intermediate

Active

Surveillance

Treatment

92%

27%

73%

27%

73%

Significant Volume Growth From Breadth and

Depth of Customer Base

•

Test utilization increased 20% throughout FY16 while ordering

physicians increased 47%

PROCEDE

1,000 Stops

Enrolling

2015

Myriad

Genetics,

Inc.,

all

rights

reserved.

www.Myriad.com.

Focused Plan to Increase Coverage for Prolaris

CURRENT MEDICARE COVERAGE:

Professional guidelines

Retrospective safety data

Prospective clinical data

Medicare precedent

NCCN guidelines

Health economic data

Low/Very Low Medicare

Medicare Advantage

EXPAND MEDICARE COVERAGE:

EXPAND PRIVATE PAYER COVERAGE:

Focused Plan to Increase Coverage for Prolaris

•

Positive coverage decision from Tufts Health Plan

•

Payer thought-leader in the Northeast represents over one million

lives

•

Covers all patients with localized prostate cancer

•

Value-based agreement

•

Assessed on % of patients choosing Active Surveillance

•

Takes

advantage

the

unique

Prolaris

Active

Surveillance

threshold

•

Approach can not be matched by other competitors and provides

template for additional contracts

Sensitivity Analysis Predicts Strong

Growth

Revenue in millions

Monte Carlo Simulation

Factor

Assumptions

Market

Growth

•

30%-50%

growth rate

•

30%-60% market

penetration

•

5%-20% international

mix

Coverage

•

80%-100% payer

coverage

Market

•

50%-80% market

Significant Unmet Need In Prostate Cancer

Treatment

Market Opportunity

•

Substantial unmet

clinical need

•

Expanded Medicare

coverage based on

additional clinical data

Key Advantages

•

Pioneering science

differentiation based

on gold standard

endpoints

•

Definitive active

surveillance threshold

•

Unmatched clinical

utility data

Commercial Breadth

and Depth

•

Largest urology sales

force in diagnostics

•

Increased physician

adoption

•

Increased test

utilization

Positioned to become standard of care in

the prostate cancer prognostic market

Revolutionizing Melanoma Diagnosis

101

Positioned to become market leader in

melanoma diagnostics

Market Opportunity

•

Significant unmet

clinical need

•

Ability to impact

physician decision

making

•

Substantial

economic value

Key Advantages

•

Pioneering science

•

Extensively validated

approach

•

One of the most

accurate cancer

diagnostics ever

developed

Commercial Breadth

and Depth

•

Significant physician

adoption

•

Increasing utilization

Traditional Melanoma Diagnosis is

Highly Subjective

15% to 47% discordance in peer reviewed literature

103

STUDY

DISCORDANCE

Cerroni

et al

47%

Hawryluk

et al

478

35%

Piepkorn

et al

149

46%

Gerami

et al

30%

Veenhuizen

et al

1,069

15%

Shoo et al

392

15%

Lodha

et al

178

25%

Farmer et al

35%

Overall

2,384

31%

430,000 Patients Receive Indeterminate Results

104

Possible

Under-

Treatment

Possible

Over-

Treatment

3.0 Million

Skin Biopsies for

Melanoma Per Year*

15%

Discordance

430,000

Indeterminate

Cases

*Includes major European countries, U.S. and Canada

Costs Increase Dramatically for Later

Stage Disease

105

Localized

Melanoma

Regional

Melanoma

Distant

Melanoma

Average

10-Year

Cost per Patient

$15,612

$29,033

$210,281

>10x

increase in costs

Undertreatment

•

Patient only

receives monitoring

•

Recurrence as later

stage melanoma

•

Reduction in

survival as disease

progresses

•

Significantly higher

cost to treat

Overtreatment

•

Psychological

implications

•

Highly invasive

surgery

•

Follow-on care

•

Permanent scarring

•

Unnecessary

comorbidities

(infection, nerve

damage, etc.)

INACCURATE DIAGNOSIS

myPath

Melanoma: The Solution

•

23 gene mRNA expression panel

(13 genes tied to immune function,

1 gene tied to cell differentiation,

5 genes tied to cell signaling)

•

Unique approach uses information

from inside and outside the cell

•

Validated in sample cohorts

containing all melanoma and benign

nevus subtypes

•

Demonstrated to be highly accurate

at differentiating melanoma from

benign skin lesions

106

Melanoma

Diagnosis Score

1 Gene

Cell

Differentiation

5 Genes

Cell

Signaling

8 Genes

Immune

Group

9 Genes

Housekeepers

One of the Most Accurate Cancer

Diagnostics Ever

107

Clinical Validation 1 (N=437)

Clinical Validation 2 (N=736)

Diagnostic Accuracy = 90%

90% sensitivity

91% specificity

AUC = 0.96

Diagnostic Accuracy = 92%

92% sensitivity

93% specificity

AUC = 0.95

myPath

Melanoma Led to a Significant

Increase in Diagnostic Confidence

108

80%

38%

Pre-Test

Post-Test

22%

Pre-Test

Post-Test

11%

41%

Pre-Test

Post-Test

Indeterminate Diagnosis

Malignant Diagnosis

Benign Diagnosis

>50% reduction in

indeterminate results

2.4x increase in diagnostic

confidence

3.7x increase in diagnostic

confidence

Drives Substantial Economic Value for the

Healthcare System

109

$776

$1,462

$333

$2,519

$1,500

$500

$1,000

$1,500

$2,000

$2,500

$3,000

$3,500

Initial Pathology

Cost Savings

Additional Initial

Treatment Costs

Cost Savings on

Advanced

Treatment

Cost of Test

Net Impact

$1,500 saved

per patient

tested

18% of Dermatopathologists

Have Used

myPath

Melanoma

110

2,000

4,000

6,000

8,000

10,000

FY14

FY15

Tests Performed

18% of U.S.

dermatopathologists

have ordered

myPath

Melanoma

Reimbursement Dossier Complete and

Awaiting Publication

111

DOSSIER

REQUIREMENT

# OF STUDIES

COMPLETE

PUBLICATION STATUS

Analytical

Validation

Published

in Biomarkers in Medicine

Clinical Validation

1 Published

in Journal of Cutaneous

Pathology

Pending publication

Clinical Utility

3 Pending publication

Health Economic

Model

Published in Journal of Medical

Economics

Guidelines/ Consensus

Statement

1 Pending publication

Sensitivity Analysis Predicts Strong

Growth

112

Revenue in millions

Monte Carlo Simulation

Factor

Assumptions

Market

Growth

•

30%-50%

growth rate

•

5%-13% market

penetration

•

5%-15% international

mix

Price

•

80%-100% payer

coverage

$76

$44

$108

$25

$50

$75

$100

$125

FY15

FY20

Average Outcome

Lower Bound of CI

Upper Bound of CI

Revolutionizing Melanoma Diagnosis

113

Positioned to become market leader in

melanoma diagnostics

Market Opportunity

•

Significant unmet

clinical need

•

Ability to impact

physician decision

making

•

Substantial

economic value

Key Advantages

•

Pioneering science

•

Extensively validated

approach

•

One of the most

accurate cancer

diagnostics ever

developed

Commercial Breadth

and Depth

•

Significant physician

adoption

•

Increasing utilization

Promising Early-Stage Pipeline Opportunities

115

Substantial

market

opportunity

Ability to leverage

existing sales channels

Outstanding

early discovery

data

Strong clinical need

for the product

Utilize existing DNA, RNA

and protein expertise

myPath

Bipolar

myPath

Prostate Cancer

myPath

Pancreatic Cancer

myPlan

Renal Cancer

Industry Leading Pipeline Facilitates

Long-Term Growth

$10B

$8B

$10B+

Stage

REIMBURSEMENT

Stage

VALIDATION

Stage

DISCOVERY

•

myRisk

•

Prolaris

•

Vectra

•

EndoPredict

•

BRACAnalysis

CDx

•

Tumor BRACAnalysis

CDx

•

myPath

Melanoma

•

myPlan

Lung Cancer

•

myChoice

HRD (Platinum)

•

myChoice

HRD

(PARP)

•

myPlan

Renal Cancer

•

myPath Bipolar

•

myPath Pancreatic Cancer

•

myPath Psoriatic Arthritis

•

myPath Prostate Cancer

•

myPath

Endometriosis

Total Addressable Market (TAM)

Ovarian Cancer, Breast Cancer, Pancreatic Cancer

Triple Negative Breast Cancer, HER2-

Breast Cancer

Ovarian Cancer, Breast Cancer, Pancreatic Cancer, Metastatic Prostate Cancer

117

Groundbreaking Science Uncovers Broadly

Applicable Signature for Cancer Prognosis

•

Cell cycle progression (CCP) genes have demonstrated broad utility

as a cancer prognostic

•

Now validated in prostate, lung, breast and renal cancers

•

Whole transcriptome

analysis shows CCP genes are the only

relevant expression targets for multiple cancers

120

*Corrected for the impact of CCP

Non-CCP Genes*

CCP Genes

Value

1.0

0.34

0.05

0.04

2x10

-7

Ability to Predict Metastases in Renal Cancer

STATISTICALLY INSIGNIFICANT

STATISTICALLY SIGNIFICANT

Substantial Clinical Need for Renal

Cancer Prognostic

121

Higher risk of significant complications

including ESRD, need for dialysis, etc.

NEPHRECTOMY

PARTIAL

NEPHRECTOMY

ACTIVE

SURVEILLANCE

•

Trend toward less invasive therapy

•

Five-year survival for stage 1 and stage 2 disease >75%

•

No existing tools to differentiate low/high-risk patients

•

90,000

patients

diagnosed

with

localized

disease

$300M

global

market opportunity

Excellent Prognostic Power Shown

in Training Data

•

Panel of 31 cell cycle

progression genes and 15

control genes (same as Prolaris)

•

Training study completed with

localized renal cancer

•

Panel was highly statistically

significant at predicting 5-year

risk of metastases; odds ratio of

3.89, p value of 0.0072

122

* Case control study in high risk population

First Look at myPlan

Renal Validation Data

123

44% of

patients have

less than a 3%

risk of 5-year

disease

mortality

•

Hazard ratio = 3.00,

p value = 1.4x10

-6

•

Next steps: present

and publish first

validation; second

validation will be

completed and

presented by 4Q16

70% of Bipolar Patients Initially Misdiagnosed

Symptoms of bipolar disorder and major depression

are almost exactly the same

125

BIPOLAR

DISORDER

•

Fatigue

•

Feelings of

worthlessness

•

Impaired concentration

•

Insomnia or hypersomnia

•

Diminished interest

in activities

•

Thoughts of suicide

•

Weight gain/loss

•

Mania

MAJOR

DEPRESSIVE

DISORDER

•

Fatigue

•

Feelings of

worthlessness

•

Impaired concentration

•

Insomnia or hypersomnia

•

Diminished interest

in activities

•

Thoughts of suicide

•

Weight gain/loss

Cost of Misdiagnosis is Substantial

•

Over 20 million patients

per year present

with symptoms consistent with major

depressive disorder (MDD) or bipolar

disorder (BP)

•

90% of patients are diagnosed by primary

care

physicians

•

Bipolar patients do not respond to first-line

or subsequent therapeutics for MDD

•

MDD anti-depressive therapeutics can

trigger manic psychosis

in a subset of

BP patients

•

BP symptoms are 6th leading cause of

disability

in 15-44 age group

•

Economic impact

of improperly treated BP

in U.S. is $72B annually

126

Outstanding Early Data Show Ability to

Differentiate Bipolar from Major Depression

127

96%

AUC in

Training Set

•

Multimarket proteomic assay run

on Myriad-RBM Luminex

platform

•

Consists of 18 protein analytes

from blood

•

Discovery completed in 150 well-

characterized BD1 and MDD

samples

•

Next steps: Validation study

sponsored by Myriad and

partnered with 3 major medical

centers; will enroll

300 patients

beginning mid-FY16

BIPOLAR

DISORDER

MAJOR

DEPRESSIVE

DISORDER

Early Detection of Pancreatic Cancer Crucial

to Survival

•

5-year survival only 7%

•

Symptoms are vague and often

misconstrued with other health

issues

•

Most early-stage patients

diagnosed through unrelated

imaging procedures

•

Only 15% of patients diagnosed

with localized/resectable

disease

•

102,000 new diagnoses annually

129

Urgent need for an early detection diagnostic

Five-Year Survival by Stage for

Pancreatic Cancer

Most patients currently

diagnosed with late-

stage disease

Promising Early Data on myPath

Pancreatic Cancer

•

136 patient study comparing 42 early-

stage pancreatic cancer cases to 94

healthy controls and patients with

chronic pancreatitis

•

92% AUC when diagnosing early stage

pancreatic cancer

•

Next steps: finalize biomarker set in

FY16

130

Proof of Principle Established for Urine-Based

Cancer Detection

•

Significant need to diagnose

urological cancers at an earlier

stage (prostate, kidney and

bladder cancer)

•

Discovery study evaluated 139

tumor samples

•

Proprietary assay was able to

differentiate patients with cancer

from healthy controls

•

Next steps: application of

technology to prostate cancer

132

0.0

0.1

0.2

0.3

0.4

0.5

0.6

0.7

0.8

0.9

1.0

0.0

0.1

0.2

0.3

0.4

0.5

0.6

0.7

0.8

0.9

1.0

Specificity

Diagnostic Accuracy = 90%

85% sensitivity

96% specificity

AUC = 0.93

Pioneering Research Fuels Industry

Leading Pipeline

•

Uniquely positioned to use all molecular diagnostic tools (DNA,

RNA, proteins) for research and development

•

Scientific output has increased >20x since FY09

140 publications per year

•

Breakthrough thinking drives discovery engine

–

Broadly applicable cancer prognosis signature

–

Proprietary cancer pathway (myChoice

HRD) test vs. gene panels

–

Addition of immune response genes for diagnosis

–

Complex multiplex protein signatures

–

Signatures combining DNA, RNA and proteins

133

Incredible Growth Opportunity in International

Markets

135

Complex reference laboratory tests, companion diagnostics and high-

value kits are most significant long-term growth drivers

Market Opportunity

•

60% of the global

market is outside of

the United States

(O.U.S.)

•

4% of revenue O.U.S.

today; goal to reach

10% by FY20

Commercial Breadth

and Depth

•

Expanding

reimbursement

•

Expand current

products to kits

Key Advantages

•

High complexity

reference lab tests

•

Companion diagnostic

partnerships

•

Kit-based strategy

Total Available Market (TAM) in 10 Major

International Markets > U.S.

136

29%

20%

40%

Long-Term

Opportunity:

>70%

U.S. Market

Source: European Federation for Pharmaceutical Industry

IFPMA Facts & Figures 2012

EU6 + Canada

Near Term

Opportunity:

50%

of U.S. Market

Key Learnings

Drive Strategic Review

137

KEY LEARNING

STRATEGY

Laboratories are captive

within institutions

Emphasize

reference tests that are too complex for

institutional laboratories (myRisk

and CDx)

Develop proprietary test kits for distribution to

institutional laboratories

Lengthy

reimbursement

throughout Europe

Acquire

German clinic

Emphasize health economic studies

Incentivize KOL involvement with kit format

Refined Strategy to Reflect Differences in

International Market

138

COUNTRIES

Near-Term

Growth:

EU6 + Canada

Long-Term

Growth:

Japan, China,

and Brazil

REFERENCE TESTS

DNA

(multiple

platforms):

Companion

Diagnostics

KITS

RNA

(platform

partner):

•

EndoPredict

•

Prolaris

•

myPlan

Lung

•

myPath

Melanoma

•

myPlan

Renal

Protein

(platform

partner):

•

Vectra DA

•

myPath

Bipolar

•

myPath

Pancreatic

Hereditary Cancer Expansion in Europe

139

•

European

market

increasingly

moving

myRisk

Hereditary

Cancer;

myRisk

was 32% of hereditary cancer revenue in the 4Q15 compared

to 23% in the 4Q14

•

Complexity of large panel tests is beyond the capability of most small,

decentralized labs

•

Beginning discussions with German hospital/physician networks

following the acquisition of MVZ clinic in 3Q15; potential for positive

impact in German market in 2H16 and beyond

•

Many private healthcare systems in major European countries now

cover myRisk

Hereditary Cancer

Companion Dx

Opportunity O.U.S. = $3B TAM

141

FY15

FY16

FY17

FY18

FY19

FY20

Tumor

BRACAnalysis

CDx

Launch

Japan, China & ROW

Ovarian

Cancer

(30,000)

Major country

reimbursement for

Lynparza

Platinum in

TNBC

(55,000)

Platinum in

HER2-

(65,000)

PARPs

in Breast

Cancer

(200,000)

PARPs in

Metastatic

Prostate

Cancer

(40,000)

PARPs

in Pancreatic

Cancer

(57,000)

Focus on EU6 and Canada

Progress with Lynparza

Launch in Europe

142

Country

Status

France

Launched

and reimbursed using temporary system

starting in March, final negotiations underway

Germany

Launched in June; G-BA assessment ongoing

Denmark/Luxembourg

Launched and reimbursed since June

Sweden/Netherlands

National

reimbursement review completed; awaiting

decision

Italy,

UK,

Spain,

Belgium,

Portugal,

Norway

National

reimbursement review process ongoing

14.6%

49.4%

80.6%

4.9%

31.2%

EndoPredict

Increases Low-Risk Group

by 340% Without Increasing Risk

144

1,702 Patients Classified

By Pathology

Intermediate Patients

Re-Classified With EndoPredict

HIGH -

45%

INT. -

10%

LOW -

HIGH -

20%

EndoPredict

Validates Kit-Based Model

•

Over 40 worldwide sites using

EndoPredict

•

Substantial preference for

in-house testing and

economic sharing

•

Faster path to reimbursement;

ability to utilize local

stakeholders as advocates

•

Attractive financial model

given stickiness of testing

once account is established

145

7 additional installations ROW

Expanded Reimbursement Will Drive Increased

International Growth

147

YEAR

FY16

FY17

FY18

FY19

FY20

Hereditary Cancer

Tumor BRACAnalysis

CDx

Major country

reimbursement

throughout FY16

myChoice

HRD

First PARP using

HRD

EndoPredict

Germnay

PMI

UK PMI/NHS

Switzerland

Germany GBA

Canada

France

Prolaris

Switzerland

UK PMI

Germany

PMI

UK NHS

France

Germany GBA

Canada

myPath

Melanoma

Germany PMI

UK PMI

Germany

GBA

Canada

Switzerland

France

No Reimbursement

Low Reimbursement

Broad Reimbursement

Incredible Growth Opportunity in International

Markets

149

Complex reference laboratory tests, companion diagnostics and high-

value kits are most significant long-term growth drivers

Market Opportunity

•

60% of the global

market is outside of

the United States

(O.U.S.)

•

4% of revenue O.U.S.

today; goal to reach

10% by FY20

Commercial Breadth

and Depth

•

Expanding

reimbursement

•

Expand current

products to kits

Key Advantages

•

High complexity

reference lab tests

•

Companion diagnostic

partnerships

•

Kit-based strategy

5-Year Outlook: Increased Growth and Financial

Leverage

151

•

Hereditary cancer

growing low single digits

•

Significant diversification

from product pipeline

•

International becomes

larger contributor

>30%

Margins

7 Products

>$50M

>10% Revenue

Growth CAGR

>10% of Revenue

from International

•

Majority of investments

are completed

•

Meaningful operating

margin improvement as

new products obtain

reimbursement

•

Prioritize internal R&D

•

Pursue accretive M&A

•

Continue opportunistic

share repurchase

Maximizing

LT Shareholder Value

Revenue Growth

Operating Leverage

Assumptions for FY16 Guidance

DOWNSIDE RISKS

BASE CASE FOR GUIDANCE

UPSIDE POTENTIAL

•

Hereditary

cancer market

losses > market growth

•

Hereditary cancer

revenue

of $638 to $649 million

•

Hereditary cancer

market losses <

market growth

•

Impact

from

expanded

payer

coverage

for colon and endometrial cancer

•

Vectra DA revenue of $50

to $55 million

•

Expanded private payer coverage

•

Medicare

reimbursement

starting later than

October 1, 2015

•

Prolaris

revenue of $10 to

$12 million

•

Private payer coverage

•

Medicare

reimbursement prior to

October 1, 2015

•

Expanded Medicare coverage

•

Pharmaceutical and Clinical

Services revenue of $40M

•

Other revenue of $12 to

$14 million

•

Reimbursement for EndoPredict,

Tumor

BRACAnalysis

CDx, myPath

Melanoma or myPlan

Lung Cancer

FY16 Guidance Covered in August

153

Myriad Meets 5-Year Revenue Growth Target

At Lower End of Sensitivity Analysis

154

Revenue in millions

Monte Carlo Simulation

Factor

Assumptions

Hereditary

Cancer

•

Revenue of $554 to

$922 million

CDx

•

Revenue of $122 to

$364 million

Vectra DA

•

Revenue of $161 to

$335 million

Prolaris

•

Revenue of $112 to

$264 million

myPath

Melanoma

•

Revenue of $44 to

$108 million

New Products Represent >50%

of FY20 Revenue

155

HEREDITARY CANCER

MYPATH MELANOMA

<50% of revenue from

hereditary cancer

COMPANION DX

VECTRA DA

PROLARIS

PHARMA & CLIN SERVICES/OTHER

Meaningful Opportunity to Leverage Existing

Sales Infrastructure

159

OPERATING LEVERAGE

CURRENT

PRODUCTS

FUTURE PRODUCTS

myRisk

BRCA CDx

EndoPredict

myChoice

HRD

myRisk

myPath

Bipolar

Vectra DA

Psoriatic

Arthritis

Prolaris

myPlan

Renal Cancer

myPath

Prostate

myPath

Melanoma

Psoriatic Arthritis

None

myPath

Bipolar

2015

Myriad

Genetics,

Inc.,

all

rights

reserved.

www.Myriad.com.

2015

Myriad

Genetics,

Inc.,

all

rights

reserved.

www.Myriad.com.

CAPITAL

ALLOCATION

PRIORITY

CAPITAL

DEPLOYMENT

SINCE JUNE 2010

GOAL

R&D

of revenue

8% to 10% of revenue

M&A

$340M

43% of FCF

•

Use cash on hand to fund smaller deals (<$100M)

•

Use cash and leverage to fund larger deals

($100M-$600M)

•

Use equity to fund strategic deals

(beyond borrowing capacity)

Repurchase

>$1B

127% of FCF

•

Target 100% of FCF

•

Reduce share repurchases based upon M&A visibility

•

Maintain cash at $100M to $200M

Dividend

None

No plans for dividend given more attractive uses of

capital

Capital Deployment Strategy

162

2015

Myriad

Genetics,

Inc.,

all

rights

reserved.

www.Myriad.com.

Internal R&D Represents Our Best Investment

$25

$50

$75

FY10

FY11

FY12

FY13

FY14

FY15

New Product Development (Stage 1 & 2)

Stage 3

INVESTMENT

EXPECTED

ROIC

Internal

R&D

33%

MYGN

historical

ROIC

20%

Acquisitions

Dependent

on deal and

market

conditions

164

R&D Grew at 27% CAGR

vs. Revenue at 15% CAGR

Acquisitions –

Opportunity For MYGN to be a

Consolidator In a Diffuse Industry

165

Short-term visibility to the

deal being accretive

Strategic fit; ability to leverage

existing commercial infrastructure

Meaningful revenue and

large market opportunity

Facilitates international

expansion; tax benefits

Characteristics

of a Myriad

acquisition

Present Value Calculation Based on 5-Year

Forecast –

Supports Continued Repurchases

167

Variable

Assumption

Capital Deployment

Share repurchases

= FCF

Discount

Rate

15%

P/E

Terminal Multiple Used

20x

Present Value

$60 per share

5-Year Outlook: Increased Growth and Financial

Leverage

168

•

Hereditary cancer

growing low single digits

•

Significant diversification

from product pipeline

•

International becomes

larger contributor

>30%

Margins

7 Products

>$50M

>10% Revenue

Growth CAGR

>10% of Revenue

from International

drivers

•

Majority of investments

are completed

•

Meaningful operating

margin improvement as

new products obtain

reimbursement

•

Prioritize internal R&D

•

Pursue accretive M&A

•

Continue opportunistic

share repurchase

Maximizing

LT Shareholder Value

Revenue Growth

Operating Leverage

Million

>$50

Products

with Revenue

What was New Today? Our Strategic Goals

170

Revenue Growth

CAGR

>10%

Operating

Margin

>30%

International

Revenue

>10%

What was New Today?

•

Transition and Expand Hereditary Cancer

–

myRisk

80% conversion and 45% of revenue

covered by long-term arrangements

–

Modeling demonstrates 5-year revenue CAGR = 3%

revenue

–

Variant database now over 40,000 and will grow to

80,000 by FY2020

–

Pricing floor based upon costs associated with high

accuracy and complexity, extensive service and

increased regulation

171

What was New Today?

(continued)

•

Diversify the portfolio

–

22 clinical studies with proprietary companion diagnostics for

DNA damaging agents

–

Early access launch for myChoice

HRD in Fall 2016

–

Signed LabCorp

agreement to increase access to Vectra DA

–

Prolaris’ unique active surveillance threshold facilitates

value-based contracting with TUFTS Health Plan

–

Successful second validation for myPath

Melanoma

–

Successful validation for myPlan

Renal Cancer

–

myPath

Bipolar demonstrates 96% AUC in training set;

beginning enrollment in prospective study

–

Proprietary technology developed for cancer detection in

urine

172

What was New Today?

(continued)

•

Increase International Contribution

–

Revised strategy defines countries, reference tests,

and kit products

–

RNA-based tests already under development with

Thermo Fischer Scientific for kit strategy

173

Worldwide Leader in Personalized Medicine

•

We are entering the golden age for personalized medicine

•

We are the pioneers of “research-based” and “education-centric”

business modeling for diagnostics

•

No company is better positioned to lead this revolution in healthcare

than Myriad

•

Our finest hour will be discovered in the days ahead

174